25 results about "Cells precursor" patented technology

The present invention relates to a system and a method for measuring and analyzing minimal residual disease (MRD) in pediatric B-cell precursor acute lymphoblastic leukemia (B-ALL) using multiparameter flow cytometry (MPFC). The invention finds application in clinical diagnostics and hematology-oncology for quantifying MRD in B-ALL patients with high sensitivity and specificity, needed for risk stratification, monitoring treatment response, and informing therapeutic decisions. The system comprises interconnected subsystems including an acquisition subsystem with an MPFC instrument, a control and file generation subsystem, and an analytical subsystem. The analytical subsystem incorporates modules for sequential data reduction, automated data cleaning, automated unsupervised data clustering, and interactive cluster analysis. Key advantages include high MRD detection sensitivity (e.g., 10⁻⁵ or 0.001%) and high specificity, without reliance on reference samples or supervised machine learning models, making it applicable in laboratories with different measuring equipment and using different panels of antibodies for identification of leukemic cells.

To provide a composition and a method for modulating an immune system in a subject.SOLUTION: A composition and a method provide means for treating and / or preventing a disease associated with deficiency and / or dysregulation of a T-cell. The composition can include: a porous scaffold, a growth factor which is present at approximately 1ng to approximately 1000ng per scaffold, and an effective amount for inducing formation of a tissue or an organ in the scaffold and mobilizing cells into the scaffold; and a differentiation factor which induces differentiation of mobilized cells into a T-cell precursor cell.SELECTED DRAWING: None

The invention provides an oligodendrocyte precursor cell line, a method, a kit and application. Specifically, the cell line comprises a first gene sequence and a second gene sequence; the first gene sequence and the second gene sequence are separated from each other; wherein the first gene sequence comprises a Sirt2 gene and a first subsequence; the second gene sequence comprises a nuclear localization signal gene and a second subsequence; wherein peptide chains independently expressed by the first subsequence and the second subsequence are free of fluorescence and can be spontaneously combined to form fluorescent protein when meeting. The cell line can be used for high-throughput screening of drugs or molecules for promoting differentiation of oligodendrocyte precursor cells, and has the advantages of low cost and high efficiency.

The present invention relates to a pharmaceutical composition and cell therapy agent for the prevention or treatment of neurological diseases, comprising Schwann cell precursors (SCPs) or Schwann cells differentiated therefrom, derived from pluripotent stem cells (PSCs) or somatic cells, and natural killer (NK) cells as active ingredients. Specifically, the Schwann cell precursors (SCPs) express at least one selected from the group consisting of GAP43, SOX10, IGFBP2, and combinations thereof; the Schwann cells (SCs) express at least one selected from the group consisting of S100B, SOX10, and combinations thereof; and the natural killer (NK) cells express CD56 + CD16 + It is characterized by expressing at least one selected from the group consisting of the and combinations thereof.

Methods for identifying, isolating and enriching neural stem and progenitor cells (NSPC) such as ventricular radial glia, outer radial glia, astrocytes, pre-oligodendrocyte precursor cells, oligodendrocyte precursor cells, oligodendrocytes, early excitatory neurons, late excitatory neurons, bipotent glial progenitors, and inhibitory neurons are provided. These methods find use in transplantation, to eliminate specific cell subsets, for experimental evaluation, as a source of lineage and cell-specific products, and the like, for example for use in treating human disorders of the central nervous system (CNS).

The invention belongs to the field of animal models, and particularly discloses a method for constructing an autism spectrum disorder mouse model through a BAF155 conditional knockout mode. According to the application disclosed by the invention, the influence of BAF155 knockout on OL development and myelin sheath formation is observed by constructing a specific BAF155 knockout mouse. A behavioral experiment further proves that deletion of BAF155 in oligodendrocyte precursor cells can cause a mouse to have a core and characteristic ASD-like behavior phenotype taking social preference disorder and repeated engraving behaviors as main behaviors. Therefore, a new gene molecule defect ASD animal model is successfully constructed, and the method has the advantages that the target is clear, ASD can be researched by inducing single gene molecule defects, an appropriate and matched animal model is provided for ASD caused by clinical BAF155 mutation, and accurate diagnosis and formulation of subsequent intervention strategies are facilitated.

Some embodiments of the method and compositions provided herein relate to methods of preparing cells expressing bispecific T cell engagers (BTCEs), and the use of such cells in certain therapies. In some embodiments, the cells are B cells or B cell precursors.

The purpose of the present disclosure is to provide highly versatile, ready-to-deliver allogenic T cells for novel coronavirus infection, and a production method therefor. The present invention provides: a method for producing a cell population for the treatment and / or prevention of SARS-CoV-2 infection and including T cells or precursor T cells that express a human T cell receptor (TCR) specific to SARS-CoV-2, said method comprising a step for causing the expression of one or more human TCRs specific to SARS-CoV-2 in T cells or precursor T cells in vitro; and a cell population for the treatment and / or prevention of SARS-CoV-2 infection and produced via said method, said cell population comprising allogenically derived T cells or precursor T cells.

The present disclosure provides methods for preparing improved populations of cells of the T lineage of, specifically, naive-like T cells that comprise naive T cells (TN), stem-cell like memory T cells (TSCM), and central memory T cells (TCM). The method is based on enrichment for cells expressing a marker of circulating innate lymphoid cell precursor cells. The present disclosure further provides populations of these naive-like T cells, compositions thereof, and uses thereof in treating immune-related disorders.

The present disclosure relates to CRISPR-related systems and components for targeting, editing and / or modulating the expression of FLI-1 (Freund Virus Leukemia Integration 1 Transcription Factor; Fli-1 prooncogene, ETS Transcription Factor) genes. The disclosure also relates to methods and uses thereof related to engineered cells comprising T cells or T cell precursors.

The invention discloses a pancreatic beta cell precursor cell transplantation chip based on human-derived iPSC (induced pluripotent stem cell) as well as a preparation method and application of the pancreatic beta cell precursor cell transplantation chip. The chip is composed of beta cell precursor cells (expressing Pdx1, Nkx6.1 and NeuroD1) and a porous degradable bracket (PCL / hyaluronic acid composite material), wherein the beta cell precursor cells (expressing Pdx1, Nkx6.1 and NeuroD1) are obtained by performing four-stage induction on autologous iPSC. The preparation method comprises the steps of autologous iPSC acquisition, beta cell precursor cell induction, three-dimensional bracket preparation and chip assembly. After the chip is implanted into the pancreas of a patient through minimally invasive surgery, precursor cells are differentiated into mature beta cells in vivo, insulin is secreted, the stent is gradually degraded, the pancreas islet function can be fundamentally improved, and the chip is used for treating type I and type II diabetes mellitus. The invention avoids immunological rejection, improves cell survival and functional stability, and has significant clinical transformation value.

The present disclosure relates to CRISPR related systems and components for targeting, editing and / or modulating PTPN2 (protein tyrosine phosphatase non-receptor type 2) gene expression. The disclosure also relates to methods and uses thereof related to engineered cells comprising T cells or T cell precursors.

The present disclosure is directed to CRISPR-related systems and components for targeting, editing, and / or modulating expression of a FLI-1 (Friend virus leukemia integration 1 transcription factor; Fli-1 Proto-Oncogene, ETS Transcription Factor) gene. The present disclosure also relates to methods and applications thereof in connection with engineered cells including T cells or T cell precursors.

The present disclosure relates to CRISPR related systems and components for targeting, editing and / or modulating CD70 (Cluster of Differentiation 70) gene expression. The disclosure also relates to methods and uses thereof related to engineered cells comprising T cells or T cell precursors.

The application discloses a HeLa cell three-dimensional culture model, a preparation method and application. HeLa cells are mixed with a collagen-sodium alginate composite hydrogel precursor solution to obtain a cell-precursor mixture, the cell-precursor mixture is mixed with a CaCl2 solution to obtain a mixed solution, and the mixed solution is placed in an incubator for standing culture for 10-60 min, so that the hydrogel is cross-linked and solidified to form a three-dimensional culture system; complete culture medium is further added for continuous culture, and a HeLa cell three-dimensional culture model is constructed. The HeLa cell three-dimensional culture model is constructed by using the hydrogel, defects existing in simulation of a tumor microenvironment by two-dimensional culture and an animal model are effectively solved, the body microenvironment can be better simulated, cells form regular three-dimensional cell spheroids, a malignant phenotype is maintained, the accuracy and repeatability of drug screening are improved, and a reliable technical platform is provided for cervical cancer mechanism research and anti-tumor drug screening.

The present application belongs to the field of animal models, and more specifically, a method for constructing an autism spectrum disorder mouse model by BAF155 conditional knockout mode is disclosed. By constructing a specific knockout BAF155 mouse, the effect of knockout BAF155 on OL development and myelination is observed. Further proved by the behavior experiment, the deletion of BAF155 in oligodendrocyte precursor cells will lead to the appearance of the core and characteristic ASD-like behavior phenotype of mice mainly with social preference disorder and repetitive stereotyped behavior. Therefore, the present application successfully constructs a new genetic molecular defect ASD animal model, and the advantage lies in that the target is clear, a single genetic molecular defect can be induced to study ASD, and a suitable and matched animal model for ASD caused by mutation of BAF155 is provided, which is helpful for precise diagnosis and subsequent intervention strategy.

The present disclosure relates to CRISPR-related systems and components for targeting, editing, and / or modulating expression of a PTPN2 (Protein Tyrosine Phosphatase Non-Receptor Type 2) gene. The present disclosure also relates to methods and applications thereof in connection with engineered immunocompetent cells including T cells or T cell precursors.

The present invention relates to a reagent panels for the measurement of minimal residual disease (MRD) associated with pediatric B-cell precursor acute lymphoblastic leukemia (B- ALL) by multiparametric flow cytometry. The reagent panel of the invention comprises a combination of antibodies directed against markers, wherein the combination of antibodies comprises i) antibodies targeting markers CD45, CD20, CD34, CD38, CD10, CD58, CD66c, CD73, CD81, CD123, CD304, CD44, CD86, CD99 and CD371, and ii) antibodies targeting markers CD19 and / or CD22, wherein the antibodies are conjugated with fluorochromes. The invention further relates to the use of said panels for detecting MRD associated with B-ALL and / or for identifying a subject at risk of developing B-ALL relapse. The invention also relates to methods of detecting MRD associated with B-ALL. Key advantages of the invention include achieving high MRD detection sensitivity (e.g., 10⁻⁵ or 0.001%) and high specificity.

The present invention relates to a pharmaceutical composition and a cell therapy agent for preventing or treating a neurological disease, comprising Schwann cell precursors (SCPs) prepared from pluripotent stem cells (PSCs) or somatic cells, or Schwann cells (SCs) differentiated therefrom; and natural killer (NK) cells as active ingredients. Specifically, the present invention is characterized in that the SCPs express one or more selected from the group consisting of GAP43, SOX10, IGFBP2, and a combination thereof; the SCs express one or more selected from the group consisting of S100B, SOX10, and a combination thereof; and the NK cells express one or more selected from the group consisting of CD56+, CD16+, and a combination thereof.

Among the various aspects of the present disclosure is the provision of compositions and methods for the generation of a supporting matrix for cells, such as stem cells and NP cells (and precursors thereof). For example, an NP cell-specific phenotype precursor cell can be an adult NP cell, such as a cell taken from the adult and degenerated intervertebral disc and / or a progenitor cell, such as stem cells, induced pluripotent cells, pluripotent cells, precursor cells, or stromal cells.

The present disclosure relates to CRISPR-related systems and components for targeting, editing, and / or modulating expression of a CD70 (Cluster of Differentiation 70) gene. The present disclosure also relates to methods and applications thereof in connection with engineered cells including T cells or T cell precursors.

The present disclosure provides biological markers which are molecular and cellular antecedents of rheumatoid arthritis (RA) flares. The present disclosure provides RNA and protein markers that can predict an RA flare one or two weeks prior to the flare. The present disclosure further provides blood circulating cells, particularly pre-inflammatory mesenchymal cells, which are cellular precursors and indicators of an impending RA flare. The present disclosure further provides methods, kits and markers for identification and monitoring of flares in RA patients and their application as markers and targets in and for treatment of rheumatoid arthritis and conditions induced or related to rheumatoid arthritis.

The present invention relates to compositions and methods for treating early T-cell precursor acute lymphoblastic leukemia (ETP T-ALL).

The present invention relates to a pharmaceutical composition and a cellular therapeutic agent for the prevention or treatment of a neurological disease, comprising as active ingredients: a Schwann cell precursor (SCP) prepared from a pluripotent stem cell (PSC) or a somatic cell, or a Schwann cell (SC) differentiated therefrom; and natural killer (NK) cells. Specifically, the SCP expresses any one or more selected from the group consisting of GAP43, SOX10, IGFBP2, and a combination thereof, the SC expresses any one or more selected from the group consisting of S100B, SOX10, and a combination thereof, and the NK cells express any one or more selected from the group consisting of CD56+, CD16+, and a combination thereof.

The invention discloses a culture solution and a culture method for separating parenchymal hepatic cells from human hepatic tissue, the culture solution comprises an AUTGC-HPM culture solution for promoting proliferation of precursor cells of the parenchymal hepatic cells and an AUTGC-HDM culture solution for inducing maturation of the precursor cells of the parenchymal hepatic cells, and the parenchymal hepatic cells which are not completely mature are obtained by mechanical shearing and enzymolysis digestion separation; according to the present invention, the proliferation of the parenchymal hepatic cell precursor cells is promoted by using the AUTGC-HPM, and the maturation of the parenchymal hepatic cell precursor cells is induced by using the AUTGC-HDM subsequently, such that the parenchymal hepatic cells highly similar to the source can be obtained in quantity by using the culture method, and the important basis is provided for the research such as drug research and development.